Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours

BJU International

Volumn 113, Issue 4, 2014, Pages 574-580

  Hollande, Clémence ^a   Colin, Pierre ^g   De La Motte Rouge, Thibault ^a   Audenet, François ^b   Yates, David R ^b   Phé, Véronique ^b   Ouzzane, Adil ^g   Droupy, Stéphane ^h   Ruffion, Alain ⁱ   De La Taille, Alexandre ^j   Guy, Laurent ^d   Cussenot, Olivier ^c   Rozet, François ^e   Xylinas, Evanguelos ^f   Zerbib, Marc ^f   Spano, Jean Philippe ^a   Khayat, David ^a   Bitker, Marc Olivier ^b   Rouprêt, Morgan ^b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL TENON   (France)

^d UNIVERSITÉ CLERMONT AUVERGNE   (France)

^e Academic Department of Urology Montsouris Institute   (France)

^f Institut Cochin   (France)

^g UNIV LILLE   (France)

^h NÎMES UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITÉ LYON 1   (France)

^j HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

chemotherapy; HNPCC; renal pelvis; ureter; urothelial carcinoma

Indexed keywords

CISPLATIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; FAMILIAL CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROURETERECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA;

CHEMOTHERAPY; HNPCC; RENAL PELVIS; URETER; UROTHELIAL CARCINOMA;

AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URETER; URETERAL NEOPLASMS;

EID: 84896397641     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12308     Document Type: Article

References (27)

1. Roupret M, Yates DR, Comperat E, et al. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol 2008; 54: 1226-1236
2. Skeldon SC, Semotiuk K, Aronson M, et al. Patients with lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol 2013; 63: 379-385
3. Lynch HT, de la Chapelle A,. Hereditary colorectal cancer. N Engl J Med 2003; 348: 919-932
4. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352: 1851-1860
5. Jover R, Zapater P, Castells A, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006; 55: 848-855
6. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257
7. Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011; 103: 863-875
8. Audenet F, Yates DR, Cussenot O, et al. The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). Urol Oncol 2013; 31: 407-413
9. Hellenthal NJ, Shariat SF, Margulis V, et al. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol 2009; 182: 900-906
10. Vassilakopoulou M, de la Motte Rouge T, Colin P, et al. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer 2011; 117: 5500-5508
11. Audenet F, Colin P, Yates DR, et al. A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool. BJU Int 2012; 110: E583-589
12. Ouzzane A, Colin P, Xylinas E, et al. Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol 2011; 60: 1258-1265
13. Berod AA, Colin P, Yates DR, et al. The role of American Society of Anesthesiologists scores in predicting urothelial carcinoma of the upper urinary tract outcome after radical nephroureterectomy: results from a national multi-institutional collaborative study. BJU Int 2012; 110: E1035-1040
14. Tejpar S, Saridaki Z, Delorenzi M, et al. Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle. J Natl Cancer Inst 2011; 103: 841-844
15. Buecher B, Cacheux W, Rouleau E, et al. Role of microsatellite instability in the management of colorectal cancers. Dig Liver Dis 2013; 45: 441-449
16. Birtle AJ, Lewis R, Johnson M, et al. Time to define an international standard of postoperative care for resected upper urinary tract transitional cell carcinoma (TCC)-opening of the peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (POUT) trial. BJU Int 2012; 110: 919-921
17. Meeks JJ, Bellmunt J, Bochner BH, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2012; 62: 523-533
18. Kaag MG, O'Malley RL, O'Malley P, et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 2010; 58: 581-587
19. Kim JE, Hong YS, Ryu MH, et al. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer. Cancer Sci 2011; 102: 1706-1711
20. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-3226
21. Xylinas E, Rink M, Margulis V, et al. Histologic variants of upper tract urothelial carcinoma do not affect response to adjuvant chemotherapy after radical nephroureterectomy. Eur Urol 2012; 62: e25-26
22. Roupret M, Zigeuner R, Palou J, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 2011; 59: 584-594
23. Roupret M, Catto J, Coulet F, et al. Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma. J Med Genet 2004; 41: e91
24. Roupret M, Fromont G, Azzouzi AR, et al. Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology 2005; 65: 1233-1237
25. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002; 20: 1043-1048
26. Kuppermann M, Wang G, Wong S, et al. Preferences for outcomes associated with decisions to undergo or forego genetic testing for Lynch syndrome. Cancer 2013; 119: 215-225
27. Lynch HT, Lynch PM,. Molecular screening for the Lynch syndrome-better than family history? N Engl J Med 2005; 352: 1920-1922